KR20150045423A - 티에노트리아졸로디아제핀 화합물을 사용하여 림프종을 치료하는 방법 - Google Patents
티에노트리아졸로디아제핀 화합물을 사용하여 림프종을 치료하는 방법 Download PDFInfo
- Publication number
- KR20150045423A KR20150045423A KR20157000782A KR20157000782A KR20150045423A KR 20150045423 A KR20150045423 A KR 20150045423A KR 20157000782 A KR20157000782 A KR 20157000782A KR 20157000782 A KR20157000782 A KR 20157000782A KR 20150045423 A KR20150045423 A KR 20150045423A
- Authority
- KR
- South Korea
- Prior art keywords
- cell
- carbon atoms
- lymphoma
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 206010025323 Lymphomas Diseases 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 title claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 46
- 201000011510 cancer Diseases 0.000 claims abstract description 42
- 230000003211 malignant effect Effects 0.000 claims abstract description 40
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims abstract description 34
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract description 33
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 27
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 206010042971 T-cell lymphoma Diseases 0.000 claims abstract description 17
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims abstract description 17
- 230000003393 splenic effect Effects 0.000 claims abstract description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- -1 4- phenylaminophenyl Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 150000004683 dihydrates Chemical class 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- FGNAJWFZOBYZLR-UHFFFAOYSA-N 3h-[1,2,4]triazolo[4,3-a][1,4]diazepine Chemical compound N1=CC=CN2CN=NC2=C1 FGNAJWFZOBYZLR-UHFFFAOYSA-N 0.000 claims 1
- 230000036210 malignancy Effects 0.000 abstract description 6
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 67
- 108020004999 messenger RNA Proteins 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 13
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 13
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 13
- 108091005625 BRD4 Proteins 0.000 description 9
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 208000017604 Hodgkin disease Diseases 0.000 description 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 7
- 101150092565 DOHH gene Proteins 0.000 description 7
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102000001805 Bromodomains Human genes 0.000 description 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- 108050009021 Bromodomains Proteins 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 108091028690 C-myc mRNA Proteins 0.000 description 3
- 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 description 3
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 2
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 2
- 102000051819 Baculoviral IAP Repeat-Containing 3 Human genes 0.000 description 2
- 101150104237 Birc3 gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 201000004085 CLL/SLL Diseases 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000037057 G1 phase arrest Effects 0.000 description 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 2
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000000564 macroglobulinemia Diseases 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical class [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 201000006845 reticulosarcoma Diseases 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 101100059544 Arabidopsis thaliana CDC5 gene Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000012526 B-cell neoplasm Diseases 0.000 description 1
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 1
- GNMUEVRJHCWKTO-UHFFFAOYSA-N Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=NC(CC(Nc(cc1)ccc1O)=O)c1nnc(C)[n]-21 Chemical compound Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=NC(CC(Nc(cc1)ccc1O)=O)c1nnc(C)[n]-21 GNMUEVRJHCWKTO-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101150115300 MAC1 gene Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000012721 SDS lysis buffer Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663885P | 2012-06-25 | 2012-06-25 | |
| US61/663,885 | 2012-06-25 | ||
| US201261670918P | 2012-07-12 | 2012-07-12 | |
| US61/670,918 | 2012-07-12 | ||
| PCT/EP2013/063313 WO2014001356A1 (en) | 2012-06-25 | 2013-06-25 | Method of treating lymphoma using thienotriazolodiazepine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150045423A true KR20150045423A (ko) | 2015-04-28 |
Family
ID=48672651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20157000782A Withdrawn KR20150045423A (ko) | 2012-06-25 | 2013-06-25 | 티에노트리아졸로디아제핀 화합물을 사용하여 림프종을 치료하는 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140018353A1 (enExample) |
| EP (1) | EP2863923B1 (enExample) |
| JP (1) | JP6265979B2 (enExample) |
| KR (1) | KR20150045423A (enExample) |
| CN (1) | CN105050605A (enExample) |
| AU (1) | AU2013283378B2 (enExample) |
| BR (1) | BR112014032105A2 (enExample) |
| CA (1) | CA2877434A1 (enExample) |
| IN (1) | IN2014DN11269A (enExample) |
| MX (1) | MX2014015986A (enExample) |
| RU (1) | RU2659171C2 (enExample) |
| WO (1) | WO2014001356A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EP3027194A1 (en) * | 2013-08-01 | 2016-06-08 | Oncoethix GmbH | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| EP3030242A1 (en) * | 2013-08-06 | 2016-06-15 | Oncoethix GmbH | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| JP2016538310A (ja) | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| SI3674302T1 (sl) | 2014-04-23 | 2023-07-31 | Incyte Holdings Corporation | 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet |
| RU2016146099A (ru) | 2014-05-02 | 2018-06-05 | Онкоэтикс Гмбх | Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений |
| JP2017514907A (ja) * | 2014-05-02 | 2017-06-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法 |
| MX2016014574A (es) | 2014-05-08 | 2017-02-23 | Oncoethix Gmbh | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. |
| AU2015273032A1 (en) | 2014-06-13 | 2016-12-15 | Oncoethix Gmbh | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
| US9968620B2 (en) | 2014-08-19 | 2018-05-15 | Oncoethix Gmbh | Methods of treating lymphoma using thienotriazolodiazepine compounds |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| KR101675984B1 (ko) | 2015-02-23 | 2016-11-14 | 한양대학교 에리카산학협력단 | 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CR20190027A (es) | 2016-06-20 | 2019-05-16 | Incyte Corp | Formas sólidas cristalinas de un inhibidor de bet |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| CN108070562A (zh) * | 2018-02-03 | 2018-05-25 | 金华市中心医院 | 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法 |
| KR20210003804A (ko) | 2018-04-13 | 2021-01-12 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레브론 리간드 및 이를 포함하는 2작용성 화합물 |
| JP7526721B2 (ja) * | 2018-09-11 | 2024-08-01 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 癌治療のためのブロモドメインＢＲＤ４阻害剤としてのｔｅｒｔ－ブチル（Ｓ）－２－（４－（フェニル）－６Ｈ－チエノ［３，２－ｆ］［１，２，４］トリアゾロ［４，３－ａ］［１，４］ジアゼピン－６－イル）アセテート誘導体及び関連化合物 |
| CN118638043A (zh) | 2019-12-19 | 2024-09-13 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
| DE69717160T2 (de) * | 1996-09-13 | 2003-05-08 | Mitsubishi Pharma Corp., Osaka | Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| EP2902030B1 (en) * | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| WO2013033420A1 (en) * | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
-
2013
- 2013-06-25 MX MX2014015986A patent/MX2014015986A/es unknown
- 2013-06-25 KR KR20157000782A patent/KR20150045423A/ko not_active Withdrawn
- 2013-06-25 CA CA2877434A patent/CA2877434A1/en not_active Abandoned
- 2013-06-25 EP EP13730912.6A patent/EP2863923B1/en not_active Not-in-force
- 2013-06-25 JP JP2015517810A patent/JP6265979B2/ja not_active Expired - Fee Related
- 2013-06-25 IN IN11269DEN2014 patent/IN2014DN11269A/en unknown
- 2013-06-25 AU AU2013283378A patent/AU2013283378B2/en not_active Ceased
- 2013-06-25 BR BR112014032105A patent/BR112014032105A2/pt not_active Application Discontinuation
- 2013-06-25 US US13/926,029 patent/US20140018353A1/en not_active Abandoned
- 2013-06-25 RU RU2015101106A patent/RU2659171C2/ru not_active IP Right Cessation
- 2013-06-25 WO PCT/EP2013/063313 patent/WO2014001356A1/en not_active Ceased
- 2013-06-25 CN CN201380045846.0A patent/CN105050605A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2877434A1 (en) | 2014-01-03 |
| BR112014032105A2 (pt) | 2017-08-01 |
| AU2013283378B2 (en) | 2017-07-13 |
| JP6265979B2 (ja) | 2018-01-24 |
| IN2014DN11269A (enExample) | 2015-10-09 |
| AU2013283378A1 (en) | 2015-01-29 |
| RU2015101106A (ru) | 2016-08-10 |
| CN105050605A (zh) | 2015-11-11 |
| MX2014015986A (es) | 2016-02-11 |
| EP2863923A1 (en) | 2015-04-29 |
| US20140018353A1 (en) | 2014-01-16 |
| RU2659171C2 (ru) | 2018-06-28 |
| EP2863923B1 (en) | 2019-05-08 |
| JP2015531747A (ja) | 2015-11-05 |
| WO2014001356A1 (en) | 2014-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150045423A (ko) | 티에노트리아졸로디아제핀 화합물을 사용하여 림프종을 치료하는 방법 | |
| Huang et al. | Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy | |
| Yang et al. | MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis | |
| Hsieh et al. | EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells | |
| CN101910182A (zh) | 抗癌剂 | |
| JP2017529358A (ja) | がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用 | |
| Liu et al. | Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1–Smad2/3 signaling | |
| RU2012154447A (ru) | Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций | |
| EP3310785B1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| WO2016004418A1 (en) | Glutaminase inhibitor therapy | |
| Bashash et al. | Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action | |
| Ebihara et al. | Nuclear factor erythroid 2-related factor 2 is a critical target for the treatment of glucocorticoid-resistant lupus nephritis | |
| AU2023210543B2 (en) | Uses of myostatin antagonists, combinations containing them and uses thereof | |
| CZ20032338A3 (cs) | Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch | |
| CN111225903A (zh) | 谷氨酰胺酶抑制剂疗法 | |
| Li et al. | Rebamipide suppresses TNF‐α mediated inflammation in vitro and attenuates the severity of dermatitis in mice | |
| KR20150081422A (ko) | mTOR 경로 관련 질병 치료를 위한 화합물 | |
| JP2019511553A (ja) | 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ | |
| Park et al. | Artemisinin inhibits lipopolysaccharide-induced interferon-β production in RAW 264.7 cells: Implications on signal transducer and activator of transcription-1 signaling and nitric oxide production | |
| Yang et al. | Mammalian target of rapamycin inhibitor rapamycin enhances anti‐leukemia effect of imatinib on P h+ acute lymphoblastic leukemia cells | |
| AU2011234644B2 (en) | PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling | |
| AU2014308700A1 (en) | Cancer treatment | |
| Zuo et al. | Inhibition of Bromodomain-Containing 4 Sensitises Aggressive Non-Hodgkin Lymphomas to Phosphatidylinositol 3-Kinase δ Inhibitors | |
| Zarei et al. | A combined therapeutic approach: Parthenolide and vincristine modulate autophagy in B-cell acute lymphoblastic leukemia | |
| EP3164195A1 (en) | Glutaminase inhibitor therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150113 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180625 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20190314 |